TY - JOUR
T1 - Leveraging the dynamic blood–brain barrier for central nervous system nanoparticle-based drug delivery applications
AU - Copeland, Connor
AU - Stabenfeldt, Sarah E.
N1 - Funding Information:
The authors thank Amanda Witten, Crystal Willingham, and Silina Souvannarath for proof reading, as well as Amanda Witten for graphical support. Funding: The authors acknowledge that this study was funded by NIH , Eunice Kennedy Shriver NICHD ( 1DP2HD084067 ; SES), NIH NINDS ( R21NS107985 ; SES), and ASU Ira A. Also, the authors are grateful to the Fulton Schools of Engineering (Dean's Fellowship; CC) for supporting this study.
Funding Information:
The authors thank Amanda Witten, Crystal Willingham, and Silina Souvannarath for proof reading, as well as Amanda Witten for graphical support. Funding: The authors acknowledge that this study was funded by NIH, Eunice Kennedy Shriver NICHD (1DP2HD084067; SES), NIH NINDS (R21NS107985; SES), and ASU Ira A. Also, the authors are grateful to the Fulton Schools of Engineering (Dean's Fellowship; CC) for supporting this study.
Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2020/6
Y1 - 2020/6
N2 - Neurological diseases and injuries have profound impact on a patient's lifespan and functional capabilities, but often lack effective intervention strategies to address the underlying neuropathology. The blood–brain barrier is a major hurdle in the effective delivery of therapeutics to the brain. Recent discoveries in blood–brain barrier maintenance reveal a dynamic system where time of day, disease progression, and even biological variables all strongly influence its permeability and flux of molecules. Nanoparticles can be used to improve the efficacy of therapeutics by increasing circulation time, bioavailability, selectivity, and controlling the rate of payload release. Considering these recent findings, the next generation of pharmacological paradigms are evolving to leverage nanotechnology to turn therapeutic intervention to meet the needs of a specific patient (i.e. personalized medicine).
AB - Neurological diseases and injuries have profound impact on a patient's lifespan and functional capabilities, but often lack effective intervention strategies to address the underlying neuropathology. The blood–brain barrier is a major hurdle in the effective delivery of therapeutics to the brain. Recent discoveries in blood–brain barrier maintenance reveal a dynamic system where time of day, disease progression, and even biological variables all strongly influence its permeability and flux of molecules. Nanoparticles can be used to improve the efficacy of therapeutics by increasing circulation time, bioavailability, selectivity, and controlling the rate of payload release. Considering these recent findings, the next generation of pharmacological paradigms are evolving to leverage nanotechnology to turn therapeutic intervention to meet the needs of a specific patient (i.e. personalized medicine).
KW - Blood–brain barrier
KW - Circadian rhythm
KW - Drug delivery
KW - Nanoparticle
KW - Traumatic brain injury
UR - http://www.scopus.com/inward/record.url?scp=85084368575&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85084368575&partnerID=8YFLogxK
U2 - 10.1016/j.cobme.2020.04.001
DO - 10.1016/j.cobme.2020.04.001
M3 - Review article
AN - SCOPUS:85084368575
SN - 2468-4511
VL - 14
SP - 1
EP - 8
JO - Current Opinion in Biomedical Engineering
JF - Current Opinion in Biomedical Engineering
ER -